BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 23384160)

  • 1. Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.
    Ridderstråle M; Jensen MM; Gjesing RP; Niskanen L
    J Med Econ; 2013; 16(4):468-78. PubMed ID: 23384160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.
    Valentine WJ; Jendle J; Saraheimo M; Thorsteinsson B; Pollock RF; Lammert M
    Diabet Med; 2012 Mar; 29(3):303-12. PubMed ID: 21951030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden.
    Smith-Palmer J; Fajardo-Montañana C; Pollock RF; Ericsson A; Valentine WJ
    J Med Econ; 2012; 15(5):977-86. PubMed ID: 22563742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Willingness-to-pay for benefits associated with basal insulin treatment of type 2 diabetes.
    Jendle J; Ridderstråle M; Torfvitt O; Ericsson A; Larsen S
    J Med Econ; 2012; 15(2):261-3. PubMed ID: 22142237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
    Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
    Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
    Ericsson Å; Pollock RF; Hunt B; Valentine WJ
    J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
    Palmer AJ; Roze S; Valentine WJ; Smith I; Wittrup-Jensen KU
    Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
    Brändle M; Azoulay M; Greiner RA
    Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany.
    Pfohl M; Schädlich PK; Dippel FW; Koltermann KC
    J Med Econ; 2012; 15 Suppl 2():14-27. PubMed ID: 22812690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries.
    Gschwend MH; Aagren M; Valentine WJ
    J Med Econ; 2009 Jun; 12(2):114-23. PubMed ID: 19545216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
    Permsuwan U; Chaiyakunapruk N; Dilokthornsakul P; Thavorn K; Saokaew S
    Appl Health Econ Health Policy; 2016 Jun; 14(3):281-92. PubMed ID: 26961276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States.
    Valentine WJ; Erny-Albrecht KM; Ray JA; Roze S; Cobden D; Palmer AJ
    Adv Ther; 2007; 24(2):273-90. PubMed ID: 17565917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes.
    Valentine WJ; Goodall G; Aagren M; Nielsen S; Palmer AJ; Erny-Albrecht K
    Adv Ther; 2008 Jun; 25(6):567-84. PubMed ID: 18568451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin analogs versus human insulin in type 2 diabetes.
    Migdalis IN
    Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S102-4. PubMed ID: 21864739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective.
    Evans M; Wolden M; Gundgaard J; Chubb B; Christensen T
    Diabetes Obes Metab; 2014 Apr; 16(4):366-75. PubMed ID: 24373113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.
    Brändle M; Azoulay M; Greiner RA
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):203-20. PubMed ID: 17474539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.
    Warren E; Weatherley-Jones E; Chilcott J; Beverley C
    Health Technol Assess; 2004 Nov; 8(45):iii, 1-57. PubMed ID: 15525480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.